Homepage Top Section1

This agreement designates Er-Kim as the distributor for the therapy in Azerbaijan, Armenia, Belarus, Georgia, Kyrgyzstan, Kazakhstan, Uzbekistan, Tajikistan, Russia, and Turkmenistan. The prescription medicine, Nerlynx, is intended

As part of this collaboration, Boehringer will utilise ExpressionEdits’ AI-powered platform, Genetic Syntax Engine, designed to boost gene expression without altering the genetic sequence, for the development of

With this investment, Gilead’s equity ownership in Assembly Bio has increased to 29.9%. These funds are expected to extend Assembly Bio’s cash runway to mid-2026 and will support

The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have

ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase

The investment round saw contributions from Gimv, HealthCap, Red Tree Venture Capital, and existing backers BioGeneration Ventures, M Ventures, and Brabantse Ontwikkelings Maatschappij (BOM). The funds will be

The CRL, dated 22 October 2024, comes ahead of the Generic Drug User Fee Amendments of 2022 (GDUFA) goal date set for 29 October 2024. Ketamine, an essential

The acquisition bolsters AscellaHealth’s capabilities to serve international manufacturers and patients in more than 70 countries across the EU, Asia, Africa, Australia and the Americas. CHAPPER healthcare is

The contract, with a maximum value of $80m over a five-year period, is part of the NIH’s Helping to End Addiction Long-term Initiative (HEAL Initiative) and falls under